McKesson Reports Strong Q4 2026 Earnings with Strategic Growth Plans
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy MCK?
Source: seekingalpha
- Strong Financial Performance: McKesson reported an adjusted earnings per diluted share of $11.69 for Q4 2026, with consolidated revenues increasing by 6% to $96.3 billion and gross profit rising by 14% to $3.9 billion, indicating robust market performance and profitability.
- Shareholder Return Initiatives: The company returned $5.1 billion to shareholders through share repurchases in fiscal 2026 and anticipates free cash flow to remain between $4.5 billion and $4.9 billion in fiscal 2027, reflecting management's confidence in future cash generation and commitment to shareholders.
- Separation Progress: McKesson is advancing its plan to spin off its Medical-Surgical Solutions segment into an independent entity, having secured a $1.25 billion strategic investment from Apollo, which is expected to unlock shareholder value and enhance strategic clarity.
- Future Growth Outlook: The company projects adjusted earnings per diluted share in the range of $43.80 to $44.60 for fiscal 2027, with revenue growth expectations of 14.5% to 18.5% in the oncology and multispecialty segment, showcasing a positive outlook on new market opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MCK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MCK
Wall Street analysts forecast MCK stock price to rise
14 Analyst Rating
12 Buy
2 Hold
0 Sell
Strong Buy
Current: 754.760
Low
880.00
Averages
942.83
High
1000.00
Current: 754.760
Low
880.00
Averages
942.83
High
1000.00
About MCK
McKesson Corporation is a diversified healthcare services company, which focuses on advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. It also offers oncology and specialty solutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
McKesson Reports Strong Q4 2026 Earnings with Strategic Growth Plans
- Strong Financial Performance: McKesson reported an adjusted earnings per diluted share of $11.69 for Q4 2026, with consolidated revenues increasing by 6% to $96.3 billion and gross profit rising by 14% to $3.9 billion, indicating robust market performance and profitability.
- Shareholder Return Initiatives: The company returned $5.1 billion to shareholders through share repurchases in fiscal 2026 and anticipates free cash flow to remain between $4.5 billion and $4.9 billion in fiscal 2027, reflecting management's confidence in future cash generation and commitment to shareholders.
- Separation Progress: McKesson is advancing its plan to spin off its Medical-Surgical Solutions segment into an independent entity, having secured a $1.25 billion strategic investment from Apollo, which is expected to unlock shareholder value and enhance strategic clarity.
- Future Growth Outlook: The company projects adjusted earnings per diluted share in the range of $43.80 to $44.60 for fiscal 2027, with revenue growth expectations of 14.5% to 18.5% in the oncology and multispecialty segment, showcasing a positive outlook on new market opportunities.
See More
Market Dynamics: Oil Prices and Tech Stocks Fluctuate
- Oil Price Recovery: West Texas Intermediate crude oil prices rebounded above $97 per barrel after a morning dip, reflecting cautious optimism about future demand, which could impact related energy stocks' performance.
- Divergent Tech Stock Performance: As AI-related stocks pull back, cybersecurity software stocks like CrowdStrike and Palo Alto Networks surged, crossing $500 and $190 respectively for the first time, indicating increased market confidence in their business models and potentially attracting more investor interest.
- Boeing Stock Rise: Boeing's shares rose as CEO Kelly Ortberg is set to accompany President Trump on his trip to China, with the market anticipating a major order of up to 500 planes, although skepticism remains regarding the order's realization.
- Employment Data Expectations: Economists forecast a 65,000 increase in April's nonfarm payrolls with the unemployment rate steady at 4.3%, while average hourly earnings are expected to rise by 3.8%, providing crucial economic health indicators that could influence investor confidence.
See More
S&P 500 Continues Record Run Fueled by AI Spending Boom
- Earnings Season Begins: Eaton is set to report earnings on Tuesday, with expectations of a roughly 200% year-over-year increase in data center orders within its Electrical Americas segment, indicating that AI buildout is driving order growth and enhancing the company's competitiveness in the data center market.
- DuPont Performance Focus: DuPont will also report on Tuesday, with its Healthcare & Water Technologies segment expected to achieve mid-single-digit organic growth, reflecting the company's strategic direction post-electronics spin-off, and investors will closely watch for commentary on changes in customer behavior.
- Arm Holdings First Earnings Call: Arm will report earnings on Wednesday, focusing on its newly launched AI central processing unit (CPU), which, although not yet on the market, is expected to drive future cloud revenue growth, with investors keen on the health of its smartphone royalty stream.
- Corning Investor Day: Corning will hold an investor day on Wednesday, expected to update its
See More
Analysis of Upcoming U.S. Jobs Report Outlook
- Job Market Expectations: According to FactSet consensus estimates, the U.S. is expected to add only 50,000 jobs in April, significantly lower than March's 178,000, indicating signs of economic slowdown that could impact investor confidence.
- Unemployment Rate Stability: The unemployment rate is anticipated to remain steady at 4.3%, suggesting that despite the decrease in job additions, the labor market remains relatively stable, potentially alleviating fears of an economic downturn.
- GDP Growth Situation: The U.S. GDP grew at a seasonally adjusted annualized rate of 2% in the first quarter, higher than the fourth quarter's 0.5% but below the 2.2% estimate, reflecting economic sluggishness that may influence future monetary policy decisions.
- Market Volatility: Despite a strong performance in April, with the S&P 500 and Nasdaq hitting record highs, investors should remain cautious of the upcoming
See More
Cardinal Health Raises 2026 Profit Forecast Amid Strong Specialty Drug Demand
- Profit Forecast Increase: Cardinal Health raised its 2026 adjusted profit forecast to between $10.7 and $10.8 per share, significantly up from the previous range of $10.15 to $10.35, reflecting strong confidence in the robust demand for high-priced specialty and branded drugs.
- Quarterly Earnings Beat: The company reported an adjusted profit of $3.17 per share for the third quarter, surpassing analyst expectations of $2.79 per share, indicating strong performance in the high-margin pharmaceuticals sector.
- Sales Miss Expectations: Despite reporting total sales of $60.9 billion for the third quarter, this figure fell short of the $61.7 billion analysts had anticipated, suggesting challenges in overall sales despite high demand.
- Specialty Drug Market Expansion: Cardinal Health is actively expanding its presence in the specialty drug market through acquisitions of physician practices and specialty care networks, aiming to diversify beyond traditional drug distribution in response to market dynamics.
See More
OpenAI Misses Revenue Targets; Coca-Cola Reports Strong Quarter
- OpenAI Revenue Decline: According to The Wall Street Journal, OpenAI fell short of its internal revenue growth and user targets, leading to a decline in its overall valuation, which negatively impacted related companies like Softbank and Oracle.
- Coca-Cola Strong Performance: Coca-Cola reported first-quarter revenue of $12.5 billion and earnings per share of $0.86, both exceeding market expectations, with a 10% organic growth indicating its robust position in the sluggish consumer goods sector despite having a few extra days in the quarter.
- UPS Steady Performance: UPS achieved top and bottom line beats in the first quarter and reaffirmed its full-year guidance, demonstrating a recovery in growth after cutting costs and winding down its partnership with Amazon.
- Spotify Growth Struggles: Despite Spotify's first-quarter earnings per share of €4.04 beating expectations, the stock fell over 8% due to a disappointing outlook for the current quarter, indicating investor concerns over its operating income and gross margin guidance.
See More
McKesson Reports Strong Q4 2026 Earnings with Strategic Growth Plans
- Strong Financial Performance: McKesson reported an adjusted earnings per diluted share of $11.69 for Q4 2026, with consolidated revenues increasing by 6% to $96.3 billion and gross profit rising by 14% to $3.9 billion, indicating robust market performance and profitability.
- Shareholder Return Initiatives: The company returned $5.1 billion to shareholders through share repurchases in fiscal 2026 and anticipates free cash flow to remain between $4.5 billion and $4.9 billion in fiscal 2027, reflecting management's confidence in future cash generation and commitment to shareholders.
- Separation Progress: McKesson is advancing its plan to spin off its Medical-Surgical Solutions segment into an independent entity, having secured a $1.25 billion strategic investment from Apollo, which is expected to unlock shareholder value and enhance strategic clarity.
- Future Growth Outlook: The company projects adjusted earnings per diluted share in the range of $43.80 to $44.60 for fiscal 2027, with revenue growth expectations of 14.5% to 18.5% in the oncology and multispecialty segment, showcasing a positive outlook on new market opportunities.
See More
Market Dynamics: Oil Prices and Tech Stocks Fluctuate
- Oil Price Recovery: West Texas Intermediate crude oil prices rebounded above $97 per barrel after a morning dip, reflecting cautious optimism about future demand, which could impact related energy stocks' performance.
- Divergent Tech Stock Performance: As AI-related stocks pull back, cybersecurity software stocks like CrowdStrike and Palo Alto Networks surged, crossing $500 and $190 respectively for the first time, indicating increased market confidence in their business models and potentially attracting more investor interest.
- Boeing Stock Rise: Boeing's shares rose as CEO Kelly Ortberg is set to accompany President Trump on his trip to China, with the market anticipating a major order of up to 500 planes, although skepticism remains regarding the order's realization.
- Employment Data Expectations: Economists forecast a 65,000 increase in April's nonfarm payrolls with the unemployment rate steady at 4.3%, while average hourly earnings are expected to rise by 3.8%, providing crucial economic health indicators that could influence investor confidence.
See More
S&P 500 Continues Record Run Fueled by AI Spending Boom
- Earnings Season Begins: Eaton is set to report earnings on Tuesday, with expectations of a roughly 200% year-over-year increase in data center orders within its Electrical Americas segment, indicating that AI buildout is driving order growth and enhancing the company's competitiveness in the data center market.
- DuPont Performance Focus: DuPont will also report on Tuesday, with its Healthcare & Water Technologies segment expected to achieve mid-single-digit organic growth, reflecting the company's strategic direction post-electronics spin-off, and investors will closely watch for commentary on changes in customer behavior.
- Arm Holdings First Earnings Call: Arm will report earnings on Wednesday, focusing on its newly launched AI central processing unit (CPU), which, although not yet on the market, is expected to drive future cloud revenue growth, with investors keen on the health of its smartphone royalty stream.
- Corning Investor Day: Corning will hold an investor day on Wednesday, expected to update its
See More
Analysis of Upcoming U.S. Jobs Report Outlook
- Job Market Expectations: According to FactSet consensus estimates, the U.S. is expected to add only 50,000 jobs in April, significantly lower than March's 178,000, indicating signs of economic slowdown that could impact investor confidence.
- Unemployment Rate Stability: The unemployment rate is anticipated to remain steady at 4.3%, suggesting that despite the decrease in job additions, the labor market remains relatively stable, potentially alleviating fears of an economic downturn.
- GDP Growth Situation: The U.S. GDP grew at a seasonally adjusted annualized rate of 2% in the first quarter, higher than the fourth quarter's 0.5% but below the 2.2% estimate, reflecting economic sluggishness that may influence future monetary policy decisions.
- Market Volatility: Despite a strong performance in April, with the S&P 500 and Nasdaq hitting record highs, investors should remain cautious of the upcoming
See More
Cardinal Health Raises 2026 Profit Forecast Amid Strong Specialty Drug Demand
- Profit Forecast Increase: Cardinal Health raised its 2026 adjusted profit forecast to between $10.7 and $10.8 per share, significantly up from the previous range of $10.15 to $10.35, reflecting strong confidence in the robust demand for high-priced specialty and branded drugs.
- Quarterly Earnings Beat: The company reported an adjusted profit of $3.17 per share for the third quarter, surpassing analyst expectations of $2.79 per share, indicating strong performance in the high-margin pharmaceuticals sector.
- Sales Miss Expectations: Despite reporting total sales of $60.9 billion for the third quarter, this figure fell short of the $61.7 billion analysts had anticipated, suggesting challenges in overall sales despite high demand.
- Specialty Drug Market Expansion: Cardinal Health is actively expanding its presence in the specialty drug market through acquisitions of physician practices and specialty care networks, aiming to diversify beyond traditional drug distribution in response to market dynamics.
See More
OpenAI Misses Revenue Targets; Coca-Cola Reports Strong Quarter
- OpenAI Revenue Decline: According to The Wall Street Journal, OpenAI fell short of its internal revenue growth and user targets, leading to a decline in its overall valuation, which negatively impacted related companies like Softbank and Oracle.
- Coca-Cola Strong Performance: Coca-Cola reported first-quarter revenue of $12.5 billion and earnings per share of $0.86, both exceeding market expectations, with a 10% organic growth indicating its robust position in the sluggish consumer goods sector despite having a few extra days in the quarter.
- UPS Steady Performance: UPS achieved top and bottom line beats in the first quarter and reaffirmed its full-year guidance, demonstrating a recovery in growth after cutting costs and winding down its partnership with Amazon.
- Spotify Growth Struggles: Despite Spotify's first-quarter earnings per share of €4.04 beating expectations, the stock fell over 8% due to a disappointing outlook for the current quarter, indicating investor concerns over its operating income and gross margin guidance.
See More
